Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):297-300. doi: 10.1007/s10096-008-0612-5. Epub 2008 Aug 21.

Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy.

Author information

Department of Pediatrics, Pediatric Infectious Diseases Unit, Catholic University of the Sacred Heart, L.go A. Gemelli, 8, 00168 Rome, Italy.

Erratum in

  • Eur J Clin Microbiol Infect Dis.2009 Jul;28(7):879. Dosage error in article text.


The purpose of this report is to evaluate the efficacy and safety of spiramycin/cotrimoxazole in the mother-to-child transmission of Toxoplasma gondii infection. We retrospectively analysed 76 infants born to mothers with toxoplasmosis during pregnancy and estimated the risk of mother-to-child transmission considering the gestational age at the time of infection. Seventy-six mothers were given spiramycin, cotrimoxazole and folinic acid; only two babies (2.6%) were infected by Toxoplasma and none of them showed signs or symptoms of congenital infection or interference of sulphamid on tetrahydrofolate reductase (THFR) either at birth or during follow-up. Treatment did not need to be stopped in any mother because of adverse drug effects. Our results seem to encourage the use of spiramycin/cotrimoxazole in women with toxoplasmosis during pregnancy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center